It was another mixed start to the day, which was worse than I would have thought given the ICPT data. Even the stocks that were moving seemed to have relatively muted moves and were giving back a substantial portion of the initial bounce. While small caps were not really outperforming large caps, it was another […]
May 20 Biotech Update
The market remains neutral in that stocks are reacting to news in predictable ways and there does not seem any real bid or selling to the sector in general. It seems like people have their positions established and are adjusting them when new information arises but other than that there does not seem to be […]
March 19 Biotech Update- Staying Focused
The trading today seemed a little calm (could be because I was out most of the morning) but this is not bad given the recent swings. A period of steady base building might be the most productive outcome but we still need to see many more days before we can be confident as to what […]
Quick Confirmation
I just talked to CNAT and confirmed that they have not seen any lipid abnormalities either at the pre-clinical or clinical stages. In addition, they noted that there is no reason to expect the emricisan mechanism of action to generate any lipid abnormalities. Obviously, this does not completely rule anything out but simply confirms my […]
March 18 Biotech Update- Cause for Optimism?
This morning was much more encouraging than yesterday with the sector finally seeming to outperform the broader market. Obviously one day does not make a trend and even despite the price action; most of it seemed on fairly light volume so this could still be the pause that refreshes for the next move down. In […]
March 17 Biotech Update- Due for a Bounce?
The sector looked good this morning but seemed more in line with the broader market and not necessarily a signal of strength. We are at a region where we should see a bounce in the IBB but the move this morning was not really encouraging. It seemed that there were more than enough sellers on […]
February 17 Biotech Update- A Presidents Day Bonus
The market is obviously closed today but I wanted to have a brief note because I am not sure I will have time to write anything significant tomorrow. 1. One question that has been in the back of my mind is M&A. I keep expecting to see more as BMY, GILD, PFE, and others have […]
February 11 Biotech Update- Some Positive Catalysts
It was a good day for the broader markets and a decent day for biotechs, although it seemed a little like a mixed bag with some stocks underperforming the rally. That being said simply following the broader market higher at this point is good for biotechs and likely means that this rally (relief or continuation) […]
January 9- The Biotech Momentum Continues
It was a great day for biotechs despite a neutral to bearish macro drag. We not only had some great price action but we continued with the positive news. This is creating a nice bid under the sector and even the large caps that did not have much news per se moved higher. It is […]
Highlights from Day 2 at Needham
Today marked the end of the 12th Annual Needham Healthcare Conference. Below is a collection of slides from companies that we are following or have an interest in. These include Chelsea Therapeutics (CHTP), Curis (CRIS), Cytokinetics (CYTK), Intercept (ICPT), Omeros (OMER), Sangamo (SGMO), TG Therapeutics (TGTX) and several others. (See our slideshow from Day 1 […]
Recent Biotech IPOs
We want to highlight some biotech companies that have recently come public. The end of 2012 and continuing into the spring of 2013 brought forward a number of companies in search of new funding across various stages of development(Phase 1-3). Initially, shares in these companies will be rather illiquid, so expect to see some volatility. […]
